I know of other companies that had multi-indication drugs -- when they had a partner for one indication, the partner had the right of first refusal on partnerships for other indications. I mentioned this possibility in my post.

I have talked to people who know about licensing deals, and they said that a big pharma wants to make sure that they are not spending the big bucks advertising the product, only to have some other company benefit from name recognition for a different indication that the other company has licensed. I was told: "companies need to choose a partner very carefully to make sure it will be able to license all the indications."

And if people are worried about a drug being suppressed -- they should think about what makes the most business sense. If a company can be a partner on one blockbuster drug with many indications, they would be fools to suppress it instead of gleaning huge profits.

But hey, what do I know.